A New Medicine for Giardiasis
Development of PTLS-209 for treatment for giardiasis
This project aims to create a new and more effective medicine called PTLS-209 for people suffering from giardiasis, especially when current drugs don't work well.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Primetime Life Sciences, LLC NIH-funded |
| Lab location | 1 site (Germantown, United States) |
| Project ID | NIH-11126885 on NIH RePORTER |
What this research studies
Giardiasis is a common waterborne infection causing severe diarrhea, and current medicines often fail or have undesirable side effects, making it a significant global health challenge, particularly for children. Researchers identified an initial promising compound, fumagillin, that effectively kills the Giardia parasite. However, fumagillin had issues with stability and potential toxicity in humans. This project has successfully improved upon fumagillin, developing PTLS-209, which is designed to be more stable, effective, and safer for treating giardiasis.
Who could benefit from this research
Good fit: Patients who have giardiasis, especially those with drug-resistant infections or who experience side effects from current medications, would be the ideal candidates for this future treatment.
Not a fit: Patients without giardiasis or those whose infections are effectively treated by existing, well-tolerated medications may not directly benefit from this specific new drug development.
Why it matters
Potential benefit: If successful, this new medicine could offer a much-needed alternative for patients with giardiasis, particularly those who don't respond to existing treatments or experience severe side effects.
How similar studies have performed: While the initial compound, fumagillin, showed promise in lab and animal models, this specific improved compound, PTLS-209, represents a novel optimization to address its limitations.
Where this research is happening
Germantown, United States
- Primetime Life Sciences, LLC — Germantown, United States (Active)
Researchers
- Principal investigator: Padia, Janak K — Primetime Life Sciences, LLC
- Study coordinator: Padia, Janak K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.